Evidence map›Paper›PMID 40269142›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2025

Effects of methamphetamine on two measures of reward: Euphoria and neural activation to reward cues.

Hanna Molla, Joseph DeBrosse, Sarah Keedy, Royce Lee, Harriet de Wit

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hanna MollaDepartment of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA.
Joseph DeBrosseDepartment of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA.
Sarah KeedyDepartment of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-2139-9271
Royce LeeDepartment of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA.
Harriet de WitDepartment of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA. hdew@uchicago.edu.ORCID http://orcid.org/0000-0002-7211-8994

Funding

Determinants of Drug Preference in Humans--Administrative SupplementR01DA002812 · NIDA · UNIVERSITY OF CHICAGO · PI DE WIT, HARRIET · 1985 to 2024
$10.6M
Institutional Career Development Core (Chapter 1)KL2TR002387 · NCATS · UNIVERSITY OF CHICAGO · PI ERIC C BEYER, Lisa L Barnes · 2017 to 2026
$7.6M
3T MRI Scanner for multidisciplinary imaging and image-guided therapyS10OD018448 · OD · UNIVERSITY OF CHICAGO · PI KARCZMAR, GREGORY S. · 2014 to 2014
$2.0M
NCATS NIH HHS KL2 TR002387NIDA NIH HHS R01 DA002812NIH HHS S10 OD018448U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS) TR002387U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA02812
6 · The paper itself

Abstract

Stimulants enhance dopamine function, affecting diverse aspects of reward function from neural processing of reward cues to feelings of well-being in humans. However, little is known about the relationships among different measures of reward function. Understanding relationships among different indices of reward processing could provide insight into the processes that control motivated behavior. The present study examined the effects of a single dose of methamphetamine on two measures of reward in healthy adults: feelings of well-being and neural activation with reward-related stimuli. In a randomized, within-subject, double-blind study, 88 healthy men and women received a single 20 mg oral dose of methamphetamine (MA) and placebo, across two sessions. Regional activations to reward-related cues were assessed using fMRI during the Monetary Incentive Delay task, and positive subjective effects of MA were assessed using standardized questionnaires. As expected, MA increased euphoria and feelings of well-being. MA had minimal effects on neural activation during either anticipation or receipt of reward, but it significantly increased ventral striatal activation during anticipation of monetary loss, suggesting heightened salience of loss-related cues. As reported previously, caudate activation during reward anticipation during the non-drug (placebo) session was correlated with euphoria induced by MA (on the MA session). However, this correlation between cue-induced neural activation and euphoria was not apparent on the MA session. Thus, MA-induced euphoria was related to reward cue-elicited neural activation only when participants were tested without the drug. MA increased neural reactivity to loss, and this was not correlated with euphoria. These findings suggest that MA can dampen reward-related neural activity normally detected in the drug-free state, and that it enhances brain responses to loss. Further research is needed to determine how neural responses to reward or loss cues are related to feelings of well-being, and how either of these affect reward-related behavior.

Indexed as

BrainCentral Nervous System StimulantsCuesEuphoriaMethamphetamineRewardAdultDouble-Blind MethodFemaleHumansMagnetic Resonance ImagingMaleYoung AdultCentral Nervous System StimulantsMethamphetamine

Identifiers

PMID40269142
PMCPMC12170867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.